3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
9
Nivolumab
5
fludarabine
4
Cyclophosphamide
4
amatuximab
3
Ipilimumab
3
Fluorouracil
3
Cisplatin
3
tislelizumab
2
spartalizumab
2
budigalimab
2
belinostat
2
Hyperthermic Intraperitoneal Chemotherapy
2
Cytoreduction Surgical Procedures
2
Carboplatin
2
venetoclax
1
talazoparib
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
epacadostat
1
durvalumab
1
bosutinib
1
atezolizumab
1
aldesleukin
1
Valacyclovir
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Blood Component Removal
×
Gynecologic
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled